Citable company snapshot
West Pharmaceutical Services's latest SEC-sourced 2026-06-30 period shows $872.30M in revenue and $154.00M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $872.30M | $844.90M | +3.2% |
| Gross Profit | Jun 30, 2026 | $329.20M | $296.40M | +11.1% |
| Operating Income | Jun 30, 2026 | $179.10M | $177.10M | +1.1% |
| Net Income | Jun 30, 2026 | $154.00M | $138.80M | +11.0% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $124.00M | $89.90M | +37.9% |
| Free Cash Flow (computed) | Jun 30, 2026 | $80.80M | $47.20M | +71.2% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Jul 23, 2026; accession 0000105770-26-000099.
WST company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.